AbbVie (ABBV) 2025 Earnings Quality Report

Grade: D — Capital Structure Under Strain

Framework: Schilit *Financial Shenanigans* + Beneish M-Score + forensic accounting principles

Data: SEC EDGAR 10-K (Filed 2026-02-20, fiscal year ended December 31, 2025) + Yahoo Finance

Auditor: Ernst & Young LLP — Clean opinion (1 Critical Audit Matter)

One-line verdict: AbbVie has successfully replaced the Humira franchise. Skyrizi and Rinvoq generated $17.6B and $12.7B respectively in 2025 — each individually larger than Humira's peak pre-biosimilar US revenue — while Humira itself fell 49% to approximately $4.4B. But the 10-K reveals the cost of that transition is carried on the balance sheet: stockholders' equity has flipped to negative $3.27B from positive $17.25B three years ago, driven by $70B of cumulative dividends and the $10B+ Cerevel and ImmunoGen acquisitions. Total debt of $67.5B is covered by just $5.2B of cash (8% coverage), the Altman Z-Score sits in distress territory at -0.62 (a mechanical outcome of negative equity), and EY's Critical Audit Matter flags $14.6B in Medicaid/Medicare rebate accruals as "complex and required significant auditor judgment." Cash flow tells the positive story — CFFO of $19.0B covers net income 4.5x over and free cash flow of $17.8B funded $11.7B in dividends while still leaving $5.4B for acquisitions. The question is whether the capital structure can absorb another shock.

Business: The Post-Humira Transition Is Complete

Per Item 1 of the 10-K: "AbbVie Inc. ('AbbVie' or the 'company') is a global, diversified research-based biopharmaceutical company." The 10-K identifies the core portfolio: "Skyrizi (risankizumab) is an interleukin-23 (IL-23) inhibitor... Rinvoq (upadacitinib) is an oral, once-daily selective and reversible JAK inhibitor... Humira (adalimumab) is a biologic therapy administered as a subcutaneous injection."

Per the MD&A product table:

The MD&A states: "Net revenues for Skyrizi increased 50% in 2025 primarily driven by continued strong market share uptake as well as market growth across all indications. Net revenues for Rinvoq increased 39% in 2025... Net revenues for Humira decreased 49% in 2025 primarily driven by continued impact of direct biosimilar competition following the loss of exclusivity."

The transition story is intact. Skyrizi + Rinvoq now generate approximately $30B — already 50% of total revenue and growing at a combined 45%+. Humira is a declining footnote.

Profitability: Cash-Rich, Accounting-Complicated

Per the consolidated statements of operations:

Net income of $4.2B is dramatically lower than EBITDA of $17.6B because of (a) $2.9B in interest expense on $67.5B of debt, (b) substantial acquired IPR&D and amortization from the Cerevel and ImmunoGen acquisitions, and (c) the 2024 R&D spike that included the $3.5B upfront cost of the Cerevel deal expensed as acquired IPR&D.

Gross margin of 70.2% is in the normal range for large pharma. The B4 check passes with a 0.2pp change.

Cash Flow: The Genuine Earnings Power

Per the consolidated statements of cash flows:

AbbVie's economic earnings power is best measured by free cash flow, not net income. FCF of $17.8B covers dividends of $11.7B with $6.1B to spare, and the 4.5x CFFO/NI ratio reflects how much accrual accounting amortization understates cash generation. The C1 (CFFO vs NI) and C2 (FCF) checks both pass by wide margins. The C3 accruals ratio of -11.1% is unusually low — a very good sign, and a direct consequence of the amortization gap between reported earnings and cash.

The $20.5B business acquisition outflow in 2024 represents the Cerevel ($8.7B) and ImmunoGen ($10.1B) deals. Another $5.4B was spent on acquisitions in 2025.

The Balance Sheet: Negative Equity

Per the balance sheet — this is the core issue:

Stockholders' equity has gone from +$17.25B to -$3.27B in three years. The combination of:

has driven equity negative. This is not uncommon among mature pharma companies that acquire aggressively and return cash to shareholders — Philip Morris, McDonald's, and several others carry negative equity — but it is a material change in AbbVie's capital structure.

C4 red flag: Cash of $5.23B covers only 8% of total debt of $67.5B. The 10-K cash flow statement describes active debt management: "repayment of $5.0 billion under the term loan credit agreement and repayments of $3.8 billion aggregate principal amount of 2.60% senior notes, 1.5 billion aggregate principal amount of 1.38% senior euro notes, 700 million aggregate principal amount of 1.25% senior euro notes, $1.0 billion aggregate principal amount of 3.85% senior notes." But the debt stack remains at $67.5B.

Altman Z-Score of -0.62 is in the distress zone. This number is mechanically driven by the negative equity — the Z-Score formula uses retained earnings/assets and equity/liabilities, both of which go negative. In AbbVie's case, the Z-Score should be read as "capital structure flag" rather than "bankruptcy risk" — FCF of $17.8B against $2.9B of interest expense produces a 6x interest coverage ratio, and Debt/EBITDA of 3.8x is healthy for a large pharma. D2 (leverage) passes.

Accounts Receivable Watch

A2 watch: AR grew 15.3% against revenue growth of 8.6%. The growth differential is meaningful but not alarming for a company whose top products (Skyrizi +50%, Rinvoq +39%) are growing much faster than the total. DSO increased 4 days.

The 18-Point Screening

Beneish M-Score components: DSRI 1.062, GMI 0.997, AQI 0.959, SGI 1.086, DEPI 1.049, SGAI 0.875, TATA -0.1105 (very low/negative), LVGI 1.041. Nothing is aggressive. The very negative TATA (total accruals to assets) is notable — it signals that AbbVie's cash earnings substantially exceed its accrual earnings, a consequence of the large non-cash amortization of acquired intangibles.

Key Risks from the 10-K (Item 1A)

1. Biosimilar and Patent Risk

Per Item 1A: "AbbVie relies on patent, trademark and other intellectual property protection in the discovery, development, manufacturing and sale of its products. Patents covering AbbVie products normally provide market exclusivity, which is important for the profitability of many of AbbVie's products. As patents for certain of its products expire, AbbVie could face competition from lower priced generic or biosimilar products."

The filing adds: "Companies have developed and are developing biosimilars that compete with AbbVie's biologic products." Humira is the cautionary tale within the 10-K itself — down 49% in a single year after biosimilar entry. Skyrizi and Rinvoq eventually face the same cliff.

2. Pricing Pressure and the Voluntary Agreement

Per Item 1A: "AbbVie is subject to increasing public and legislative pressure with respect to pharmaceutical pricing." The 10-K discloses a specific concession: "In January 2026, AbbVie entered into a voluntary agreement with the United States government to provide certain pricing concessions... Such arrangements could also influence pricing expectations or negotiations in other markets or with other payers."

The filing adds: "In major markets worldwide, governments play a significant role in funding health care services and determining the pricing and reimbursement of pharmaceutical products." Medicare price negotiation under the Inflation Reduction Act is an ongoing threat to the portfolio.

3. Pipeline and Collaboration Dependency

Per Item 1A: "A portion of AbbVie's near-term pharmaceutical pipeline relies on collaborations with third parties, which may adversely affect the development and sale of its products." This includes the Cerevel neuroscience pipeline (emraclidine, tavapadon) and multiple oncology collaborations.

4. Manufacturing Complexity

Per Item 1A: "The successful discovery, development, manufacturing and sale of biologics is a long, expensive and uncertain process... manufacturing biologics, especially in large quantities, is often complex and may require the use of innovative technologies. Such manufacturing also requires facilities specifically designed and validated for this purpose."

The filing also warns about raw material concentration: "AbbVie uses raw materials and components in its pharmaceutical and biologic manufacturing processes that may be sourced from single suppliers. AbbVie cannot guarantee that it will be able to reach agreement with alternative providers."

5. Reliance on Third Parties

Per the filing: "Certain aspects of AbbVie's operations are highly dependent upon third party service providers. Reliance on third party manufacturers reduces AbbVie's oversight and control of the manufacturing process."

Auditor's Critical Audit Matter: $14.6B in Rebate Accruals

Ernst & Young LLP issued an unqualified opinion. The Critical Audit Matter is Sales rebate accruals for Medicaid, Medicare and managed care programs:

Per the audit report: "At December 31, 2025, the Company had $14,572 million in sales rebate accruals, a large portion of which were for rebates accrued for pharmacy benefit managers, state government Medicaid programs, insurance companies that administer Medicare drug plans and private entities for Medicaid, Medicare and managed care programs. In order to establish the rebate accruals, the Company estimated its rebates based on estimates and assumptions, including the determination of the related payer of the rebate based on sales trends, changes in rebate contracts which impacts the applicable price and rebate terms, and the corresponding lag in payment timing."

EY explains why this is a CAM: "Auditing the Medicaid, Medicare and managed care sales rebate accruals was complex and required significant auditor judgment because the accruals consider multiple subjective and complex estimates and assumptions."

$14.6B in rebate accruals is 24% of revenue. Pharmaceutical companies bill at list price and rebate enormous sums to PBMs and government payers. The true net revenue depends on the accuracy of these accrual estimates. EY's audit procedures included "independently calculating the sales rebate accruals based on historical payments and performing a hindsight analysis on the reserves recorded" — standard practice, but the scale alone warrants the CAM disclosure.

Key Financial Trends (4-Year)

Summary

Grade: D. One red flag plus two watch items, compounded by a negative-equity balance sheet that pulls the Altman Z-Score into distress territory.

AbbVie's operating reality is excellent. Skyrizi and Rinvoq have fully replaced Humira's revenue contribution at combined growth rates of 45%+, and the 10-K shows total revenue growing 8.6% even as Humira collapsed 49%. Cash generation is extraordinary — $19.0B of operating cash flow against $4.2B of net income is a 4.5x coverage ratio, one of the highest in large pharma. Free cash flow of $17.8B covered the $11.7B dividend with $6B to spare.

But the 18-check screen flags the capital structure:

The 10-K's Critical Audit Matter discloses $14.6B in Medicaid/Medicare rebate accruals — the largest estimation risk in the financials, and one that EY flagged as "complex and required significant auditor judgment."

AbbVie's earnings quality is not in doubt. The cash flow story is clean. The question is whether the capital structure can absorb another shock — a clinical pipeline setback, a larger-than-expected Medicare IRA price cut, or a new Rinvoq safety signal. Read the 10-K. Read the rebate accrual footnote. Then decide whether negative equity is acceptable for the franchise quality AbbVie offers.

**Disclaimer**: This report is based on AbbVie's fiscal year 2025 10-K filed with the SEC on February 20, 2026. This is NOT investment advice.

**About EarningsGrade**: We screen earnings reports for financial red flags using an 18-point forensic framework. Grade D means material concerns were identified that warrant investigation.